Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Patent
1993-02-22
1995-05-30
Stone, Jacqueline
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
424 946, 514565, A61K 3750, A61K 3119
Patent
active
054199018
ABSTRACT:
Reducing plasma levels of endogenous arginine by parenteral administration of arginine depleting agent reduces nitric oxide levels and results in blood pressure increase. Preferably arginase is administered intravenously to raise blood pressure. The arginase can be administered in conjunction with arginine antagonists to potentiate the effect of these. Duration of action and avoidance of antigenicity may be obtained by use in conjunction with a carrier or modifier.
REFERENCES:
patent: 2663668 (1953-12-01), Vrat
patent: 2834713 (1958-05-01), Robbins
patent: 4282217 (1981-08-01), Baglioni et al.
patent: 4734438 (1988-03-01), Macri
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5196195 (1993-03-01), Griffith
patent: 5286739 (1994-02-01), Kilbourn et al.
Aisaka, K., Biochemical and Biophysical Research Communications, 163, No. 2, 710-717 (Sep. 1989).
Hibbs, J. B., et al., The Journal of Immunology, 138, No. 2, 550-565 (1987).
Jackson, J. A., et al., J. Pharmacol. Expt. Ther. 209, 271-274 (1979).
Aisaka, K., et al., Biochemical and Biophysic Research Communications, vol. 160, No. 2, pp. 881-886, Apr. 28, 1989.
Iyengar, R., et al., Proc. Natl. Acad. Sci, USA, vol. 84, pp. 6369-6373 Sep. 1987.
Palmer, R. M. J., et al, Nature (London), 333, pp. 664-666, 1988.
Rees, D. D. et al., Proc. Natl. Acad. Sci. USA, vol. 86, pp. 3375-3378, May 1989.
Ko, R. Y. C., et al., J. Biomed. Res. 10, 249-258 (1976).
Olanoff, L. S., et al., J. Biomed. Res. 8, 125-136 (1977).
Savoka, K. V., etal., Biochem. Biophys. Acta 578, 47-53 (1979).
Blethen, S. L., et al., J. Biol. Chem., vol. 243, No. 8, 1671-1677 (1968).
Mitchell, J. A., et al., European Journal of Pharmacology, 182, 573-576 (1990).
Olken, N. M., et al., Biochem. Biophys. Res. Comm., vol. 177, No. 2, 828-833 (Jun. 14, 1991).
Stuehr, D. J., et al., Proc. Natl. Acad. Sci. USA, vol. 88, 7773-7777 (Sep. 1991).
Taylor, H., et al. (ed.), Methods in Enzymology, vol. XVIIA, pp. 310-317, 135-340, Academic Press, 1970.
Yui, Y., et al. J. Biol. Chem., vol. 266, No. 19, 12544-12547, 1991.
Stuehr, D. J. et al., Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cystol: Requirement for Inducible and Constitutive Components, Biochem. Biophys. Res. Commun., (1989) vol. 161, 420-426.
Stuehr, D. J. et al., Activated Murine Macrophages Secrete a Metabolite of Arginine with the Bioactivity of Endothelium-Derived Relaxing Factor and the Chemical Reactivity of Nitric Oxide, J. Exp. Med., (1989) vol. 169, 1011-1020.
Rees, D. D. et al., Role of Endothelium-Derived Nitric Oxide in the Regulation of Blood Pressure, Proc. Natl. Acad. Sci. U.S.A., (1989) vol. 86, 3375-3378.
Aisaka, K. et al., N.sup.G -Methylarginine, An Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in vivo, Biochem. Biophys. Res. Commun. (1989) 160:881-886.
Natanson, C. et al., Endotoxin and Tumor Necrosis Factor Challenges in Dogs Simulated the Cardiovascular Profile of Human Septic Shock, Journal of Exp. Med. (1989) 169:823-832.
Schmidt, H. et al., Arginine is a Physiological Precursor of Endothelium-Derived Nitric Oxide, Eur. J. Pharmacology (1988) 154:213-216.
Palmer, R. M. J. et al., L-Arginine is the Physiological Precursor for the Formation of Nitric Oxide in Endothelium-Dependent Relaxation, Biochem. Biophys. Res. Commun. (1988) 153:1251-1256.
Sakuma, I. et al., Identification of Arginine as a Precursor of Endothelium-Derived Relaxing Factor, Proc. Natl. Acad. Sci U.S.A. (1988) 85:8664-8667.
Palmer, R. M. J. et al., Vascular Endothelial Cells Synthesize Nitric Oxide from Arginine, Nature, (1988) vol. 333, 664-666.
Hibbs, J. B. et al., Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule, Biochem. Biophys. Res. Commun. (1988) 157:87-94.
Marletta, M. A. et al., Macrophage Oxidation of L-Arginine to Nitrite and Nitrate: Nitric Oxide Is an Intermediate, Biochemistry (1988) 27:8706-8711.
Palmer, R. M. J. et al., Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor, Nature (1987) 327:524-526.
Stuehr, D. J. et al., Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infection, Lymphokines, or Interferoy-.gamma., J. of Immunology (1987) 139:518-525.
Iynegar, R. et al., Macrophage Synthesis of Nitrite, Nitrate and N-Nitrosamines: Precursors and Role of the Respiratory Burst, Proc. Natl. Acad. Sci. U.S.A. (1987) vol. 84, 6369-6373.
Turan et al., Acta Chimica Academiae Scientiraum Hungaricae (1975) 85:327-332.
Kilbourn et al., N.sup.G -Methyl-L-Arginine Inhibits Tumor Necrosis Factor-Induced Hypotension: Implications for the Involvement of NItric Oxide Proc. Natl. Acad. Sci. U.S.A. (1990) 87:3629-3632.
Moncada, S., et al., Pharmacological Reviews 43(2):109-142 (1991).
Billiar, T. R., Journal of Leukocyte Biology 48:565-569 (1990).
Griffith, O. W., et al., The Role of Plasma Arginine in Nitric Oxide Synthesis: Studies with Arginase-Treated Rats, from the Book of Abstracts, Second International Meeting "Biology of Nitric Oxide,", handed out Sep. 29, 1991.
Pallacios, M., et al., Biochemical and Biophysical Research Communications, vol., 165, No. 2, 802-809 (1989).
Cornell Research Foundation Inc.
Stone Jacqueline
LandOfFree
Use of arginase to control nitric oxide formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of arginase to control nitric oxide formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of arginase to control nitric oxide formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-359934